NEW YORK, December 21, 2016 /PRNewswire/ --
This morning, Stock-Callers.com observes the performances of these Medical Appliances and Equipment equities: Boston Scientific Corp. (NYSE: BSX), EnteroMedics Inc. (NASDAQ: ETRM), Abbott Laboratories (NYSE: ABT), and Medtronic PLC (NYSE: MDT). These stocks belong to the Healthcare sector which was slightly lower in late trading on Tuesday, December 20th, 2016. As per a NASDAQ report, the NYSE Health Care Index slipped 0.2%, while shares of health care companies in the S&P 500 declined about 0.1% as a group. Download the free research reports on these stocks today: http://stock-callers.com/registration
Marlborough, Massachusetts headquartered Boston Scientific Corp.'s shares rose 0.28%, finishing Tuesday's trading session at $21.53. A total volume of 7.52 million shares was traded. In the last one month and since the start of this year, the stock has advanced 0.89% and 16.76%, respectively. The Company's shares are trading below their 50-day moving average by 0.72%. Moreover, shares of Boston Scientific, which develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide, have a Relative Strength Index (RSI) of 54.66.
On December 13th, 2016, Boston Scientific announced the close of its acquisition of certain manufacturing assets and capabilities of the Neovasc, Inc., an advanced biological tissue business. With the completion of the acquisition, Boston Scientific will integrate certain manufacturing assets and biologic tissue capabilities into its structural heart business for use in the manufacturing of the Lotus™ Valve System* and future heart valve technologies. The two organizations announced a definitive agreement on December 02nd, 2016 for Boston Scientific to acquire the advanced biologic tissue capabilities and make a 15% equity investment in Neovasc, for a total of $75 million in cash. See our free and comprehensive research report on BSX at: http://stock-callers.com/registration/?symbol=BSX
On Tuesday, shares in St. Paul, Minnesota headquartered EnteroMedics Inc. recorded a trading volume of 16.12 million shares, which was above their three months average volume of 10.47 million shares. The stock ended the session 6.19% lower at $0.05. The Company's shares are trading 33.22% below their 50-day moving average. Furthermore, shares of EnteroMedics, which focuses on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases, and other gastrointestinal disorders, have an RSI of 40.28.
On December 15th, 2016, EnteroMedics announced an assessment of real-world, clinical practice weight loss data in patients using the Company's vBloc® Therapy in combination with vBloc® Achieve, which confirms previously reported positive results from the ReCharge Pivotal Trial. These data show similar mean percent total weight loss (TWL) through six (9%) and nine months (10%) compared to results from the rigorous ReCharge Pivotal Trial (9% at 6 months; 10% at 9 months). The data was collected at vBloc Institutes across the US. vBloc Institutes are facilities that have integrated vBloc Therapy and vBloc Achieve into their practices. ETRM free research report PDF is just a click away at:
Shares in Abbott Park, Illinois headquartered Abbott Laboratories closed at $38.19, slightly down 0.39% from the last trading session. The stock recorded a trading volume of 6.99 million shares. The Company's shares are trading 3.44% below their 50-day moving average. Additionally, shares of Abbott Labs, which manufactures and sells health care products worldwide, have an RSI of 41.82.
On December 09th, 2016, Abbott Labs' board of directors announced an increase in the Company's quarterly common dividend to $0.265 per share from $0.260 per share. This marks the 372nd consecutive quarterly dividend to be paid by the Company since 1924. The cash dividend is payable February 15th, 2017, to shareholders of record at the close of business on January 13th, 2017. Sign up for your complimentary report on ABT at: http://stock-callers.com/registration/?symbol=ABT
At the closing bell yesterday, shares in Dublin, Ireland headquartered Medtronic PLC ended 0.90% lower at $72.44. A total volume of 6.85 million shares was traded, which was higher than their three months average volume of 5.93 million shares. The stock is trading below its 50-day moving average by 8.18%. Furthermore, shares of Medtronic, which manufactures and sells device-based medical therapies worldwide, have an RSI of 33.85.
On November 23rd, 2016, research firm Stifel reiterated its 'Hold' rating on the Company's stock with a decrease of the target price from $91 a share to $81 a share.
On December 09th, 2016, Medtronic's board of directors approved the Q3 FY17 cash dividend of $0.43 per ordinary share, representing a 13% increase over the prior year. Medtronic is a constituent of the S&P 500 Dividend Aristocrats index, having increased its annual dividend payment for the past 39 consecutive years. The dividend is payable on January 13th, 2017, to shareholders of record at the close of business on December 23rd, 2016. Register for free on Stock-Callers.com and download the latest research report on MDT at: http://stock-callers.com/registration/?symbol=MDT
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://stock-callers.com/legal-disclaimer/
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA